MoneyWorks4Me

Suven to present positive Preclinical, Phase-1 clinical data of advanced molecules at Sleep 2018

01 Jun 2018 Evaluate

Suven Life Sciences (Suven) will participate and present positive Preclinical and Phase-1 clinical data of advanced molecules from their portfolio of new chemical entities (NCEs) at Sleep 2018, A Joint Meeting of The American Academy of Sleep Medicine and The Sleep Research Society being held at Baltimore, MD, USA during June 2-6, 2018.

SLEEP is the premier world forum to present and discuss the latest developments in clinical sleep medicine and sleep and circadian science.

The SLEEP meeting provides evidence-based education to advance the science and clinical practice of sleep medicine, disseminates cutting-edge sleep and circadian research, promotes the translation of basic science into clinical practice.

During the conference Suven will present their Phase 2 ready differentiated Clinical stage therapeutic candidate SUVN-G3031 (Histamine-3 receptor antagonist) for the treatment of Narcolepsy and Narcolepsy associated with Cataplexy. Narcolepsy is a commercially attractive space with a large unmet need. The data presentation highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.


Suven Life Sciences Share Price

367.70 -4.15 (-1.12%)
27-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.50
Dr. Reddys Labs. 1175.00
Cipla 1419.90
Lupin 2164.60
Zydus Lifesciences 1189.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: